NTRC is Drug Discovery in Netherlands that focus on platform engages business. Founded in 2011. They cover business area such as developer, new and innovative approach, small molecule drug discovery, research, molecular drug, cell-base assay, protein crystallography, medicinal chemistry, therapeutic service, oncology, autoimmune disease, neurodegenerative disease, physician, their specific need, a short time, proper treatment, their patient.
2011
( 13 years old in 2024 )
Platform Engages
-
P.O. Box 280
5340 AG Oss
Netherlands
Private
developernew and innovative approachsmall molecule drug discoveryresearchmolecular drugcell-base assayprotein crystallographymedicinal chemistrytherapeutic serviceoncologyautoimmune diseaseneurodegenerative diseasephysiciantheir specific needa short timeproper treatmenttheir patient
* We use standard office opening hours in near NTRC's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
NTRC is Drug Discovery business from Netherlands that founded in 2011 (13 years old in 2024), NTRC business is focusing on Platform Engages.
NTRC headquarter office and corporate office address is located in P.O. Box 280 5340 AG Oss Netherlands.
NTRC was founded in Netherlands.
In 2024, NTRC is currently focus on platform engages sector.
Above is snippet of Google Trends for "platform engages" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with NTRC, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
